Insider Stock Trading History of Celgene Corp /de/


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Celgene Corp /de/ since year 2005. The trader's CIK number is 816284. At the time of this reporting, Celgene Corp /de/ is the 10% Owner of Acceleron Pharma Inc . (stock ticker symbol XLRN). See this page for all insider trading activities at Acceleron Pharma Inc .

Note that in the past CELGENE CORP /DE/ also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Celgene Corp /de/ since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-09-25 XLRN Acceleron Pharma Inc Buy 745,592 37.00 27,586,904
2017-04-24 AGIO Agios Pharmaceuticals Inc Buy 624,575 49.50 30,916,462
2017-04-24 AGIO Agios Pharmaceuticals Inc Buy 624,575 49.50 30,916,462
2017-04-24 AGIO Agios Pharmaceuticals Inc Buy 624,575 49.50 30,916,462
2017-02-27 ALQA Alliqua, Inc. Buy 4,000,000 .50 2,000,000
2017-02-01 JNCE Jounce Therapeutics, Inc. Buy 625,000 16.00 10,000,000
2016-10-24 CRSP Crispr Therapeutics Ag Buy 800,150 14.00 11,202,100
2016-01-11 XLRN Acceleron Pharma Inc Buy 800,000 40.00 32,000,000
2015-05-04 ALQA Alliqua, Inc. Buy 659,340 4.55 2,999,997
2014-07-08 GBIM Globeimmune Inc Buy 200,000 10.00 2,000,000
2014-05-05 XLRN Acceleron Pharma Inc Buy 1,100,000 42.86 47,146,000
2014-04-14 ALQA Alliqua, Inc. Buy 714,286 7.00 5,000,002
2014-02-10 EPZM Epizyme, Inc. Buy 340,000 29.25 9,945,000
2014-01-28 XLRN Acceleron Pharma Inc Buy 300,000 50.00 15,000,000
2013-09-24 XLRN Acceleron Pharma Inc Buy 666,667 15.00 10,000,005
2013-06-05 EPZM Epizyme, Inc. Buy 66,666 15.00 999,990

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Celgene Corp /de/ (10% Owner of Acceleron Pharma Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.